Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
24 05 2021
Historique:
received: 30 04 2020
accepted: 16 04 2021
entrez: 25 5 2021
pubmed: 26 5 2021
medline: 10 8 2021
Statut: epublish

Résumé

Esophageal adenocarcinoma (EAC) is associated with a marked genomic instability, which underlies disease progression and development of resistance to treatment. In this study, we used an integrated genomics approach to identify a genomic instability signature. Here we show that elevated expression of this signature correlates with poor survival in EAC as well as three other cancers. Knockout and overexpression screens establish the relevance of these genes to genomic instability. Indepth evaluation of three genes (TTK, TPX2 and RAD54B) confirms their role in genomic instability and tumor growth. Mutational signatures identified by whole genome sequencing and functional studies demonstrate that DNA damage and homologous recombination are common mechanisms of genomic instability induced by these genes. Our data suggest that the inhibitors of TTK and possibly other genes identified in this study have potential to inhibit/reduce growth and spontaneous as well as chemotherapy-induced genomic instability in EAC and possibly other cancers.

Identifiants

pubmed: 34031527
doi: 10.1038/s42003-021-02125-x
pii: 10.1038/s42003-021-02125-x
pmc: PMC8144613
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

617

Subventions

Organisme : BLRD VA
ID : I01 BX001584
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA155258
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA100707
Pays : United States

Références

Nature. 2007 Nov 22;450(7169):509-14
pubmed: 17965729
Int J Cancer. 2009 Nov 15;125(10):2349-59
pubmed: 19670330
Nat Cancer. 2020 Feb;1(2):249-263
pubmed: 32118208
Oncotarget. 2017 Dec 11;9(3):3081-3088
pubmed: 29423030
Blood. 2009 Mar 5;113(10):2290-7
pubmed: 19050310
N Engl J Med. 1986 Aug 7;315(6):362-71
pubmed: 2874485
Nat Commun. 2018 Aug 22;9(1):3363
pubmed: 30135448
Lab Invest. 2007 May;87(5):466-72
pubmed: 17310216
Carcinogenesis. 2016 Dec;37(12):1161-1169
pubmed: 27655834
Gastroenterology. 2004 May;126(5):1337-46
pubmed: 15131795
BMC Bioinformatics. 2011 Dec 17;12:480
pubmed: 22177264
Oncotarget. 2015 Aug 28;6(25):21064-73
pubmed: 26046797
J Cell Biochem. 2018 Sep;119(9):7540-7555
pubmed: 29904936
Br J Pharmacol. 2017 Jun;174(12):1810-1825
pubmed: 28299790
EMBO J. 2002 Jan 15;21(1-2):175-80
pubmed: 11782437
Oncol Lett. 2018 Sep;16(3):2823-2832
pubmed: 30127868
Cell Cycle. 2018;17(10):1268-1278
pubmed: 29888640
J Transl Med. 2012 Jul 09;10:141
pubmed: 22776426
Br J Cancer. 2016 Aug 9;115(4):403-10
pubmed: 27441494
J Clin Invest. 2020 Feb 3;130(2):958-973
pubmed: 31961339
Br J Cancer. 2017 Aug 22;117(5):725-733
pubmed: 28728164
J Gastroenterol Hepatol Res. 2017;6(1):2286-2295
pubmed: 29399538
Cancer Sci. 2009 Aug;100(8):1502-9
pubmed: 19459850
Blood Cancer J. 2018 Sep 25;8(10):92
pubmed: 30301882
Cancer Prev Res (Phila). 2014 Jan;7(1):114-27
pubmed: 24253313
Blood Adv. 2019 Dec 10;3(23):3968-3972
pubmed: 31805191
Oncogene. 2014 Mar 20;33(12):1495-505
pubmed: 23604115
Oncogene. 2011 Aug 18;30(33):3585-98
pubmed: 21423218
World J Gastroenterol. 2008 Jul 7;14(25):4070-6
pubmed: 18609693
Nature. 2008 May 1;453(7191):56-64
pubmed: 18451855
PLoS One. 2015 Oct 02;10(10):e0139435
pubmed: 26431531
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Sci Transl Med. 2018 Jan 17;10(424):
pubmed: 29343623
Nat Protoc. 2015 Jan;10(1):205-15
pubmed: 25551665
Nat Genet. 2015 Sep;47(9):1047-55
pubmed: 26192918
Genome Res. 2017 Jun;27(6):902-912
pubmed: 28465312
Curr Opin Genet Dev. 2014 Feb;24:52-60
pubmed: 24657537
Nat Commun. 2014;5:2997
pubmed: 24429703
Exp Cell Res. 2019 Dec 1;385(1):111669
pubmed: 31605696
Br J Cancer. 2018 Jun;118(12):1586-1595
pubmed: 29736010
Nat Genet. 2015 Sep;47(9):1038-1046
pubmed: 26192915
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Oncogene. 2019 Feb;38(6):852-867
pubmed: 30177840
Clin Cancer Res. 2009 May 15;15(10):3305-14
pubmed: 19417022
J Transl Sci. 2019 Apr;5(2):
pubmed: 30873294
Cancer Prev Res (Phila). 2016 Nov;9(11):828-834
pubmed: 27623934

Auteurs

Subodh Kumar (S)

Dana Farber Cancer Institute, Boston, MA, USA.
Veterans Administration Healthcare System, Boston, MA, USA.

Leutz Buon (L)

Dana Farber Cancer Institute, Boston, MA, USA.

Srikanth Talluri (S)

Dana Farber Cancer Institute, Boston, MA, USA.
Veterans Administration Healthcare System, Boston, MA, USA.

Marco Roncador (M)

Dana Farber Cancer Institute, Boston, MA, USA.

Chengcheng Liao (C)

Dana Farber Cancer Institute, Boston, MA, USA.
Veterans Administration Healthcare System, Boston, MA, USA.

Jiangning Zhao (J)

Dana Farber Cancer Institute, Boston, MA, USA.
Veterans Administration Healthcare System, Boston, MA, USA.

Jialan Shi (J)

Dana Farber Cancer Institute, Boston, MA, USA.
Veterans Administration Healthcare System, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Chandraditya Chakraborty (C)

Dana Farber Cancer Institute, Boston, MA, USA.

Gabriel Gonzalez (G)

Veterans Administration Healthcare System, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Yu-Tzu Tai (YT)

Dana Farber Cancer Institute, Boston, MA, USA.

Rao Prabhala (R)

Dana Farber Cancer Institute, Boston, MA, USA.
Veterans Administration Healthcare System, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Mehmet K Samur (MK)

Dana Farber Cancer Institute, Boston, MA, USA.

Nikhil C Munshi (NC)

Dana Farber Cancer Institute, Boston, MA, USA.
Veterans Administration Healthcare System, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Masood A Shammas (MA)

Dana Farber Cancer Institute, Boston, MA, USA. Masood_Shammas@DFCI.Harvard.edu.
Veterans Administration Healthcare System, Boston, MA, USA. Masood_Shammas@DFCI.Harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH